An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

Mark H Gotfried; Carlos E Girod; Danielle Antin-Ozerkis; Tracy Burgess; Indiana Strombom; John L Stauffer; Klaus-Uwe Kirchgaessler; Maria L Padilla

doi:10.1007/s41030-018-0053-y

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

Pulm Ther. 2018 Jun;4(1):59-71. doi: 10.1007/s41030-018-0053-y. Epub 2018 Apr 5.

Authors

Mark H Gotfried¹, Carlos E Girod², Danielle Antin-Ozerkis³, Tracy Burgess⁴, Indiana Strombom⁴, John L Stauffer⁴, Klaus-Uwe Kirchgaessler⁵, Maria L Padilla⁶

Affiliations

¹ Pulmonary Associates, Phoenix, AZ, USA. m.gotfried@pulmonaryassociates.com.
² The University of Texas Southwestern Medical Center, Dallas, TX, USA.
³ Yale School of Medicine, New Haven, CT, USA.
⁴ Genentech, Inc., South San Francisco, CA, USA.
⁵ F. Hoffmann-La Roche Ltd., Basel, Switzerland.
⁶ Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

Introduction: PIPF-002 was a phase 2, multicenter, open-label study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or other types of pulmonary fibrosis (PF). PIPF-002 terminated after pirfenidone became commercially available in the United States. The goal of PIPF-002 was to characterize the long-term safety of pirfenidone in these patients.

Methods: Between August 2003 and September 2006, 83 patients (IPF: 81, PF: 2) enrolled. Patients received pirfenidone in three divided doses daily, with the maintenance dose and schedule determined by enrollment group assignment. Treatment continued until patient withdrawal or study termination (2015). Treatment-emergent adverse events (TEAEs) were assessed by descriptive statistics.

Results: At baseline, median age was 70 years, mean percent predicted forced vital capacity was 67.7%, 33.7% of patients had cardiac disorders, 51.8% had gastroesophageal reflux disease, and 63.9% were receiving concomitant prednisone. Median pirfenidone dose and exposure duration were 2400 mg/day and 3.0 years, respectively. Cumulative total exposure was 279.7 patient-exposure years (PEY). Most patients (98.8%) reported ≥ 1 TEAE, with an overall incidence rate of 460.5 per 100 PEY. The most frequent TEAEs (incidence rate per 100 PEY) were nausea (23.6), IPF progression (16.1), fatigue (11.8), dyspnea (11.4), upper respiratory tract infection (11.4), and cough (10.7). Serious TEAEs were reported in 49 patients; the most frequent serious TEAEs were IPF progression and pneumonia. The most common reason for discontinuation was TEAEs (35 patients; 12.5 patients per 100 PEY), most frequently IPF progression and nausea. Overall, 21 patients died (7.5 per 100 PEY); 16 deaths were IPF-related.

Conclusions: Long-term safety and tolerability of pirfenidone findings in this study were consistent with the known safety profile of pirfenidone; no new safety signals were identified. These data support the continued use of pirfenidone in patients with IPF.

Funding: F. Hoffmann-La Roche Ltd./Genentech, Inc.

Trial registration: ClinicalTrials.gov identifier, NCT00080223. Plain language summary available for this article.

Keywords: IPF; Pirfenidone; Safety.

Associated data

ClinicalTrials.gov/NCT00080223